Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

SHE:300683 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	160.77	419.15	510.22	748.48	184.05	460.82
Short-Term Investments	-	4.56	0.3	142.75	491.39	288.73
Trading Asset Securities	593.53	449.69	578.71	144.04	514.4	250.39
Cash & Short-Term Investments	754.3	873.4	1,089	1,035	1,190	999.94
Cash Growth	-28.09%	-19.81%	5.21%	-12.99%	18.99%	-14.91%
Accounts Receivable	301.19	300.78	254.58	233.21	264.48	231.6
Other Receivables	4.17	0	0	-	3.18	0.45
Receivables	305.36	300.78	254.58	233.21	270.15	235.28
Inventory	109.92	108.98	117.41	120.18	71.65	69.63
Other Current Assets	29.35	23.18	26.98	55.47	50.88	23.44
Total Current Assets	1,199	1,306	1,488	1,444	1,583	1,328
Property, Plant & Equipment	721.55	729.69	734.56	654.23	519.63	348.63
Long-Term Investments	16.28	16.58	27.08	88.89	65.29	5
Goodwill	263.59	263.59	263.59	302.15	316.17	316.45
Other Intangible Assets	247.75	253.44	276.88	90.37	90	95
Long-Term Deferred Tax Assets	121.84	119.94	109.47	80.59	71.64	57.63
Long-Term Deferred Charges	33.18	34.49	31.96	2.62	2.39	2.61
Other Long-Term Assets	217.94	212.57	39.51	43.87	49.87	32.96
Total Assets	2,821	2,937	2,971	2,707	2,698	2,187
Accounts Payable	59.05	64.35	52.08	58.05	51.72	50.6
Accrued Expenses	15.58	79.11	59.86	46.51	46.42	37.49
Short-Term Debt	7.21	7.22	7.32	30.03	33.04	6.49
Current Portion of Long-Term Debt	10.12	14.83	14.66	7.31	3.21	-
Current Portion of Leases	-	5.12	4.8	0.7	1.87	-
Current Income Taxes Payable	5.09	3.87	2.84	2.46	4.52	2.45
Current Unearned Revenue	63.99	77.54	116	97.99	66.38	44.68
Other Current Liabilities	90.76	111.21	88.58	41.68	42.09	225.59
Total Current Liabilities	251.79	363.26	346.15	284.73	249.25	367.31
Long-Term Debt	20.8	11.52	26.32	40.92	48.17	-
Long-Term Leases	4.63	5.36	10.4	2.59	3.64	-
Long-Term Unearned Revenue	86.25	84.25	30.47	27.9	22.59	21.94
Long-Term Deferred Tax Liabilities	14.51	14.74	16.48	13.11	7.25	7.94
Other Long-Term Liabilities	45.92	45.92	45.92	2.45	23.56	64.43
Total Liabilities	423.9	525.05	475.73	371.7	354.46	461.62
Common Stock	130.89	130.89	130.89	122.1	122.1	103.36
Additional Paid-In Capital	1,837	1,837	1,837	1,557	1,557	987.76
Retained Earnings	410.05	423.98	510.34	631.16	645.19	617.54
Total Common Equity	2,378	2,392	2,478	2,310	2,324	1,709
Minority Interest	19.31	19.8	17.37	24.79	18.65	16.29
Shareholders' Equity	2,397	2,412	2,496	2,335	2,343	1,725
Total Liabilities & Equity	2,821	2,937	2,971	2,707	2,698	2,187
Total Debt	42.76	44.05	63.5	81.55	89.92	6.49
Net Cash (Debt)	711.54	829.35	1,026	953.73	1,100	993.45
Net Cash Growth	-27.93%	-19.14%	7.55%	-13.29%	10.72%	-15.46%
Net Cash Per Share	5.44	6.34	7.90	7.48	10.34	9.53
Filing Date Shares Outstanding	130.89	130.89	130.89	122.1	122.1	103.36
Total Common Shares Outstanding	130.89	130.89	130.89	122.1	122.1	103.36
Working Capital	947.14	943.07	1,142	1,159	1,333	960.99
Book Value Per Share	18.17	18.27	18.93	18.92	19.04	16.53
Tangible Book Value	1,867	1,875	1,938	1,918	1,918	1,297
Tangible Book Value Per Share	14.26	14.32	14.80	15.71	15.71	12.55
Buildings	-	500.14	500.38	398.72	350.14	174.04
Machinery	-	528.75	480.61	339.05	291.83	228.39
Construction In Progress	-	11.02	2.99	120.99	34.27	80.14

Updated Oct 22, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.